Monthly Archives: November 2011

Psychiatry’s Diagnosis Manual Under Fire – will feed culture of overdrugging/overdiagnosing

The “bible” of American psychiatry – a manual of mental health used around the world by doctors, consumers and insurance providers – has come under fire from a growing group of psychologists who worry that proposed revisions will feed into a culture of overdiagnosing, and overtreating, otherwise healthy people.

The Diagnostic and Statistical Manual of Mental Disorders, or the DSM, is undergoing its fifth major revision in the more than 60 years since it was first published by the American Psychiatric Association. The last update was in 1994, and the new manual is expected to be released in spring 2013.

Instead of drugs, children need a good dose of parenting

The targeting of preschoolers by the academy is an integral part of a disturbing tendency to advocate medical and pharmaceutical intervention as a legitimate option for the management of childhood behaviour. The campaign, which has as its premise the conviction that children’s behavioural problems represent a marker for mental illness, implicitly assumed a coercive and intrusive form. In Australia, draft guidelines being considered by the National Health and Medical Research Council threaten parents who refuse to medicate children diagnosed with ADHD with being referred to child protection authorities. The proposed guidelines assert that “as with any medical intervention” the “inability of parents to implement strategies may raise child protection issues”.

NY Times—Payments to Doctors by Pharma Raise Issues of Conflicts, CCHR warns of tainted mental health policies

The financial relationships raise questions about the influence of drug companies on prescribing patterns or research results. The practice “puts patients and tax dollars at risk,” said Lee Spiller, the policy director for the Texas branch of the Citizens Commission on Human Rights, a nonprofit mental health watchdog. “It taints the whole process. I’d hate to think donations were shaping state mental health policy in particular.”

J&J drug protocols cost taxpayers millions—Lawsuit claims Investigator fired after going public on J&J’s anti-psychotic drug campaign

Allen Jones was curious.

Why did Pennsylvania use a computer program that often pointed to a Johnson & Johnson drug over other, cheaper medicine to treat certain mental illnesses, the investigator for the Keystone State’s Office of Inspector General wanted to know. While the computer program mandated doctors use a new line of anti-psychotic drugs, including Risperdal, sold by J&J’s subsidiary Janssen companies, Jones said he couldn’t find government-funded medical studies showing that these new drugs were any more effective than their generic predecessors.

Israel Health Ministry: Use of ADHD drugs soars by 76% in 2010

Ministry figures recently passed on to Citizens Commission on Human Rights, a psychiatric and human rights violations watchdog, show 621 kilograms of methylphenidate were issued in 2010, compared with 352 kilograms in 2009.

The 2010 figures show the steepest increase since surveillance on Ritalin and Concerta marketing in Israel began in 1993. The surveillance is required since these drugs contain the active ingredient methylphenidate, which is classified in Israel as a dangerous drug.